/day) or risperidone (mean modal dose of 5.2 mg/day), analyzed the cognitive benefits of both medications. Cognitive assessments including memory, verbal fluency and executive function, as well as a social skills performance-based measure, were conducted at baseline and at endpoints. Data showed that both SEROQUEL and risperidone were associated with overall improvements in cognitive functioning (p<0.01) versus baseline, with no significant differences between the treatment groups (p= 0.84).
1
"Deficits in social functioning are a major barrier to recovery in schizophrenia," added Dr. Harvey. "The results of this study show that SEROQUEL at an appropriate dose has a beneficial effect on social competence even at 8 weeks, with part of this improvement associated with improvements in memory and speed of cognitive processing."
Treatment Compliance
In an analysis of a large health claims database, also presented today, that studied 7,216 antipsychotic monotherapy treatment episodes in patients with schizophrenia, several atypical antipsychotics (SEROQUEL, risperidone, olanzapine, and ziprasidone) and conventional antipsychotics (haloperidol, perphenazine, thioridazine, and thiothixene) were compared with respect to treatment compliance and duration of treatment.
- Data showed that patients in the atypical antipsychotic group experienced greater treatment compliance than patients in the conventional antipsychotic group.2
"In serious mental illnesses such as schizophrenia, treatment compliance is crucial to the overall management of the condition," said Kitty Rajagopalan, Ph.D., Director, Health Economics and Outcomes Research, AstraZeneca Pharmaceuticals LP. "Effective treatments such as SEROQUEL, when taken persistently, help ensure improved patient outcomes."
ABOUT SCHIZOPHRENIA
Schizophrenia is a serious brain disorder with symptoms including distorted perceptions of
'"/>
23-May-2005
Page: 1 2 3 4 Related medicine news :1.
Cognitive therapy can reduce post-traumatic stress in survivors of terrorist attacks2.
High BMI Tied to Poor Cognitive Function in Middle-Aged Adults3.
Cognitive behavioral therapy appears more effective than sleep medication for treating insomnia4.
Cognitive impairment appears to be common in ALS patients5.
Cognitive therapy reduces repeat suicide attempts by 50 percent6.
Cognitive therapy effective in preventing repeat suicide attempts7.
Cognitive therapy works as well as antidepressants, but with lasting effect after therapy ends8.
New treatment boosts muscle function in myasthenia gravis9.
Penn study finds pro-death proteins required to regulate healthy immune function10.
Journal Sleep: Longer CPAP use at night can normalize ones daytime functioning11.
Human stem cell treatment restores motor function in paralyzed rats